Impact of comorbidities on the management of psoriasis

Current Problems in Dermatology

Volumn 38, Issue , 2009, Pages 21-36

  Gerdes, S ^a   Mrowietz, U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETRETIN; FUMARIC ACID; METHOTREXATE; NICOTINE;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMORBIDITY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERTENSION; LIFE EXPECTANCY; METABOLIC SYNDROME X; OBESITY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; SKIN CANCER; LIFESTYLE; PATHOLOGY; POLYPHARMACY; RISK FACTOR;

HUMANS; LIFE STYLE; POLYPHARMACY; PSORIASIS; RISK FACTORS;

EID: 70350512850     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000232302     Document Type: Review

References (60)

1. Khan MA: Update on spondyloarthropathies. Ann Intern Med 2002;136:896-907.
2. Reich K, Kruger K, Mossner R, Augustin M: Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1,511 patients with plaque-type psoriasis. Br J Dermatol 2009. E-pub ahead of print.
3. Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M: Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006;22:989-1000.
4. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ: Clustering of inflammatory bowel disease with immune mediated diseases among members of a Northern California-managed care organization. Am J Gastroenterol 2007;102:1429-1435.
5. Wolf N, Quaranta M, Prescott N, Allen M, Smith R, Burden AD, et al: Psoriasis is associated with pleio-tropic susceptibility loci identified in type II diabetes and Crohn's disease. J Med Genet 2008;45: 114-116.
6. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463.
7. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, et al: Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122:201-206.
8. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-290.
9. Neurath MF: IL-23: a master regulator in Crohn disease. Nat Med 2007;13:26-28.
10. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-592. (Pubitemid 46220818)
11. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371: 1675-1684. (Pubitemid 351671884)
12. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al: Efficacy and safety of usteki-numab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674. (Pubitemid 351671883)
13. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al: Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351: 2069-2079.
14. Reich K, Huffmeier U, Konig IR, Lascorz J, Lohmann J, Wendler J, et al: TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007;56:2056-2064.
15. Li C, Wang G, Gao Y, Liu L, Gao T: TNF-alpha gene promoter -238G>A and -308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol 2007;127:1886-1892.
16. Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P: Association of TNF-alpha polymorphisms in Crohn disease. Hum Immunol 2005;66: 56-59.
17. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB: The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126: 2194-2201.
18. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, et al: Risk of malignancies in psoriasis patients treated with cyclo-sporine: a 5 y cohort study. J Invest Dermatol 2003; 120:211-216.
19. Hannuksela-Svahn A, Pukkala E, Laara E, Poikolainen K, Karvonen J: Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-590.
20. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
21. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-328.
22. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73.
23. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J: Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216:152-155. (Pubitemid 351158580)
24. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-3072.
25. Fortes C, Mastroeni S, Leffondre K, Sampogna F, Melchi F, Mazzotti E, et al: Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005;141:1580-1584.
26. Naldi L, Chatenoud L, Linder D, Belloni FA, Peserico A, Virgili AR, et al: Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-67.
27. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al: Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141:1527-1534.
28. Higgins E: Alcohol, smoking and psoriasis. Clin Exp Dermatol 2000;25:107-110.
29. Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CE: Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008;158:138-140.
30. Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world -a growing challenge. N Engl J Med 2007;356:213-215.
31. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-835. (Pubitemid 44556851)
32. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006;64:355-365.
33. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al: Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-1251.
34. Setty AR, Curhan G, Choi HK: Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167:1670-1675.
35. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741. (Pubitemid 44547793)
36. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al: Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-276.
37. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA: High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-1080. (Pubitemid 47237336)
38. Giannotti G, Landmesser U: Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007;32: 568-572.
39. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, et al: Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-293. (Pubitemid 47164092)
40. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-1840.
41. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S: Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 2005;85:299-303.
42. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U: Comedication related to comorbidi-ties: a study in 1,203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-1123.
43. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52: 262-267.
44. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al: National Psoriasis Foundation clinical consensus on psoriasis comor-bidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-1042.
45. Salvarani C, Lo SG, Macchioni P, Cremonesi T, Rossi F, Mantovani W, et al: Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995;22:1499-1503.
46. Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, et al: Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984;23:246-250.
47. Zachariae H: Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-447.
48. Alenius GM, Stenberg B, Stenlund H, Lundblad M, Dahlqvist SR: Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002;29:2577-2582.
49. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA: Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-873.
50. Zanolli MD, Wikle JS: Joint complaints in psoriasis patients. Int J Dermatol 1992;31:488-491.
51. Jajic Z, el Assadi G: Prevalence of psoriatic arthritis in a population of patients with psoriasis (in Croatian). Acta Med Croatica 2003;57:323-326. (Pubitemid 37356286)
52. Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT: Incidence of psoriasis in Rochester, Minn, 1980-1983. Arch Dermatol 1991;127:1184-1187.
53. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al: Epidemiology of psori-atic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573.
54. Pavlica L, Peric-Hajzler Z, Jovelic A, Sekler B, Damjanovic M: Psoriatic arthritis: a retrospective study of 162 patients. Vojnosanit Pregl 2005;62:613-620.
55. Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D: Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005;15: 279-283.
56. Biondi OC, Scarpa R, Oriente P: Prevalence and clinical features of juvenile psoriatic arthritis in 425 pso-riatic patients. Acta Derm Venereol Suppl (Stockh) 1994;186:109-110.
57. Lindegard B: Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304.
58. Mallbris L, Granath F, Hamsten A, Stahle M: Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54:614-621.
59. Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, et al: The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16:319-323.
60. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al: Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007;87:506-509.